

Court Confirms Globus Device Infringes Medtronic Patents

MEMPHIS, Tenn., Feb 09, 2011 (BUSINESS WIRE) --

Medtronic (NYSE:MDT) announced today that the United States Court of Appeals for the Federal Circuit affirmed that the Pivot system offered by Globus Medical infringes two patents owned by Medtronic.

"We are pleased by the Court's ruling," said Doug King, vice president and general manager of Medtronic's Spine business.

"The decision validates the solid patents we have protecting our minimally invasive portfolio and we remain committed to vigorously defending important intellectual property brought to us through inventing surgeons."

The decision validates a jury's previous finding in October 2008 that the claims of specific Medtronic CD HORIZON(R) SEXTANT(R) patents are valid and were infringed by Globus Medical.

The patents are related to the CD HORIZON(R) SEXTANT(R) System, a surgical instrumentation system that offers a minimally invasive method of placing implants that provide stabilization during spinal fusion surgery.

About the Spine Business at Medtronic

The Spine business, based in Memphis, Tenn., is the global leader in today's spine market and is committed to advancing the treatment of spinal conditions. The Spine business collaborates with world-renowned surgeons, researchers and innovative partners to offer state-of-the-art products and technologies for neurological, orthopaedic and spinal conditions. Medtronic is committed to developing affordable, minimally invasive procedures that provide lifestyle friendly surgical therapies. More information about the company and its spinal treatments can be found at www.medtronicspinal.com and its patient-education Web sites, www.back.com, www.iscoliosis.com, www.maturespine.com and www.necksurgery.com.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

SOURCE: Medtronic, Inc.

Medtronic, Inc.
Victor Rocha
Public Relations
901-399-2401
or
Jeff Warren
Investor Relations
763-505-2696